BLB&B Advisors LLC lowered its holdings in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,045 shares of the medical equipment provider’s stock after selling 690 shares during the quarter. BLB&B Advisors LLC’s holdings in Zimmer Biomet were worth $1,584,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Zimmer Biomet by 5,200.0% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 988 shares in the last quarter. Summit Trail Advisors LLC grew its position in shares of Zimmer Biomet by 8,836.9% during the first quarter. Summit Trail Advisors LLC now owns 127,887 shares of the medical equipment provider’s stock worth $128,000 after purchasing an additional 126,456 shares in the last quarter. Regent Investment Management LLC purchased a new stake in shares of Zimmer Biomet during the second quarter worth about $201,000. Azimuth Capital Management LLC purchased a new stake in shares of Zimmer Biomet during the second quarter worth about $201,000. Finally, Aries Wealth Management purchased a new stake in shares of Zimmer Biomet during the second quarter worth about $202,000. Hedge funds and other institutional investors own 87.18% of the company’s stock.

ZBH has been the subject of several research analyst reports. Raymond James increased their target price on Zimmer Biomet from $135.00 to $145.00 and gave the stock an “outperform” rating in a research report on Monday, July 30th. Zacks Investment Research upgraded Zimmer Biomet from a “sell” rating to a “hold” rating in a research report on Sunday, July 8th. Morgan Stanley increased their target price on Zimmer Biomet from $140.00 to $149.00 and gave the stock an “overweight” rating in a research report on Thursday. Robert W. Baird raised their price target on Zimmer Biomet from $121.00 to $132.00 and gave the company a “neutral” rating in a report on Monday, July 30th. Finally, ValuEngine upgraded Zimmer Biomet from a “sell” rating to a “hold” rating in a report on Wednesday, July 25th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $135.55.

In related news, CEO Bryan C. Hanson acquired 410 shares of the stock in a transaction dated Friday, August 31st. The stock was acquired at an average cost of $123.03 per share, with a total value of $50,442.30. Following the purchase, the chief executive officer now directly owns 25,487 shares of the company’s stock, valued at $3,135,665.61. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Chad F. Phipps sold 30,100 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $132.37, for a total value of $3,984,337.00. The disclosure for this sale can be found here. 0.71% of the stock is owned by company insiders.

NYSE ZBH opened at $123.30 on Friday. The company has a market cap of $26.75 billion, a price-to-earnings ratio of 15.26, a PEG ratio of 2.41 and a beta of 1.08. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.41 and a quick ratio of 1.25. Zimmer Biomet Holdings Inc has a 1-year low of $104.28 and a 1-year high of $134.55.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.88 by $0.04. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.99 billion. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.08 EPS. As a group, research analysts forecast that Zimmer Biomet Holdings Inc will post 7.66 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 31st. Stockholders of record on Friday, September 28th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, September 27th. Zimmer Biomet’s payout ratio is 11.96%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Further Reading: Google Finance

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.